Fulton Bank N.A. Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Fulton Bank N.A. increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 28.9% during the fourth quarter, Holdings Channel reports. The firm owned 1,343 shares of the biopharmaceutical company’s stock after acquiring an additional 301 shares during the quarter. Fulton Bank N.A.’s holdings in Alnylam Pharmaceuticals were worth $316,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in ALNY. Geode Capital Management LLC increased its stake in Alnylam Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after acquiring an additional 66,928 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Alnylam Pharmaceuticals by 3.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock worth $134,035,000 after acquiring an additional 16,756 shares during the last quarter. Avoro Capital Advisors LLC increased its stake in Alnylam Pharmaceuticals by 33.3% in the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after acquiring an additional 100,000 shares during the last quarter. Swiss National Bank increased its stake in Alnylam Pharmaceuticals by 0.3% in the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Eagle Asset Management Inc. increased its stake in Alnylam Pharmaceuticals by 25.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock worth $85,889,000 after acquiring an additional 63,385 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $237.98 on Friday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The stock has a market capitalization of $30.69 billion, a price-to-earnings ratio of -90.83 and a beta of 0.34. The stock has a fifty day simple moving average of $249.60 and a two-hundred day simple moving average of $259.41. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. Alnylam Pharmaceuticals’s revenue was down 33.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.15 EPS. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. This represents a 10.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,122 shares of company stock worth $2,540,455 in the last three months. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on ALNY shares. Sanford C. Bernstein reduced their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Cantor Fitzgerald reissued a “neutral” rating and set a $220.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Scotiabank boosted their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. Finally, HC Wainwright reissued a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.